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Abstract  17 
 18 
Obesity is a major public health issue and an important contributor to the global burden of chronic 19 
disease and disability. Studies indicate that fish and omega 3 polyunsaturated fatty acids (n3-PUFA) 20 
supplements may help prevent cardiovascular and metabolic diseases. However, the effect of fish-oil 21 
on body composition is still uncertain, so we performed a systematic review of randomized controlled 22 
trials and the first meta-analysis on the association between fish or fish oil intake and body 23 
composition measures. We found evidence that participants taking fish or fish oil lost 0.59 kg more 24 
body weight than controls (95% CI: -0.96 to -0.21). Treatment groups lost 0.24 kg/m2 (BMI) more 25 
than controls (-0.40 to -0.08), and 0.49 % more body fat than controls (-0.97 to -0.01). Fish or fish oil 26 
reduced waist circumference by 0.81 cm (-1.34 to -0.28) compared to control. There was no difference 27 
for fat mass and lean body mass. Further research is needed to confirm or refute our findings and to 28 
reveal possible mechanisms by which n3-PUFAs might reduce weight.  29 
  30 
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Introduction 31 
 32 
Obesity is a major public health issue and an important contributor to the global burden of chronic 33 
disease and disability (1).  For more than two decades, the prevalence and incidence of obesity 34 
worldwide has reached pandemic proportions (1, 2). Its association with deleterious outcomes such as 35 
type 2 diabetes, heart disease, and depression, and its direct relation to increased all-cause mortality 36 
and reduced life expectancy (1, 3, 4) make it a pressing global health problem.   37 
Attempts to control the epidemic of obesity usually target behaviour and environmental aspects of the 38 
problem. World Health Organization strategy consists of a range of long-term measures, including 39 
primary prevention, weight maintenance, management of complications and weight loss (5). However, 40 
the global obesity epidemic continues despite these measures, indicating that new approaches are 41 
needed. 42 
A much-debated approach is consumption of omega 3 polyunsaturated fatty acids (n3-PUFA, 43 
including eicosapentaenoic acid, EPA, and docosahexanoic acid, DHA), either through eating fish 44 
(which contain n3-PUFA) or taking supplements in the form of fish oil capsules. There is a growing 45 
evidence that n3-PUFA have beneficial effects on health, including prevention of cardiovascular 46 
diseases like stroke and coronary heart disease (6, 7), and metabolic diseases like dyslipidemia (8, 9). 47 
However, the influence of n3-PUFA on body composition is unclear.   48 
Ecological studies in several countries indicate that a diet rich in fish is associated with low body 49 
weight (10). Several clinical studies suggest that fish oils and n3-supplements support weight-loss 50 
diets (11, 12), but the benefit was not evident in other studies (13, 14). A narrative review of these 51 
studies supported the argument that n3-PUFA may reduce obesity (15), while a systematic review of 52 
clinical trials that assessed the effects of dietary n3-PUFA on body weight in adults reported that four 53 
out of five studies did not show any important change (16). Only few randomized controlled trials 54 
assessed the influence of whole fish, and therefore a combination of fish oil and fish protein, on 55 
weight loss. These studies showed a similar effect of whole fish compared to fish oil, even when lean 56 
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fish was used, suggesting a potential role of fish protein in weight loss (17-19). To date, no meta-57 
analysis on this subject has been done.  58 
We undertook a systematic review and meta-analysis of randomized controlled trials to assess the 59 
evidence for an effect of fish or fish-oil on body composition. 60 
Methods 61 
Databases and search strategy 62 
 63 
We conducted and reported the present meta-analysis according to the Cochrane Handbook of 64 
Systematic Reviews on Interventions (20) and the PRISMA guideline (21). We searched the electronic 65 
databases Medline, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) 66 
(search last updated on 1 May 2013). The search strategy was combined for all exposures and 67 
outcomes of interest. Search terms included Fish, seafood, salmon, tuna, cod, anchovy, bass, bream, 68 
dogfish, eel, haddock, halibut, herring, huss, mackerel, monkfish, mullet, plaice, red snapper, rock, 69 
sardines, pilchards, skate, sole, swordfish, trout, turbot, n3 fatty acid, n3 supplement*, n3 pufa, n3 70 
polyunsaturated fatty acid, omega-3, eicosapentaenoic acid, EPA, docosahexanoic acid, DHA, and 71 
were combined with terms related to body composition: obesity, adiposity, body mass index, BMI, 72 
weight, waist, waist-to-hip ratio, WHR, fat, adipose, overweight, Quetelet index, diet, body 73 
composition. Where possible, we used MeSH headings (or other standardized indexing terms). The 74 
search was restricted to humans, but unrestricted for publication date or language (see supporting 75 
information document S1 for Medline search strategy. Search strategies for Embase and CENTRAL 76 
were similar). The reference lists of all included studies were examined to identify studies not found 77 
by the search of electronic databases. The references of all studies found were entered into an 78 
electronic database (Reference Manager, version 12, Thompson Reuters) and duplicates were 79 
removed.  80 
  81 
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Eligibility criteria 82 
 83 
The titles and abstracts of retrieved references were checked for inclusion or exclusion, according to 84 
the following pre-established criteria. We included randomized controlled trials in men or women and 85 
individuals of any ethnicity that reported body composition measures as primary or secondary 86 
outcomes. The exposures were fish or n3-PUFA derived exclusively from fish. Outcome measures 87 
were BMI, body fat percentage, body weight, waist circumference, hip circumference, waist-to-hip- 88 
ratio, lean body mass, or other measures of body composition. We excluded studies that used n3-89 
PUFA from vegetal sources, and RCTs with a crossover design that did not report results at cross-90 
over. We also excluded studies that aimed to increase body weight for cachectic patients (22, 23) or 91 
newborns (24, 25). See flowchart in Figure 1 for details on the identification of eligible studies. Two 92 
independent reviewers (NB, MP) assessed eligibility and reached consensus by discussion.  93 
Data extraction 94 
 95 
Two independent reviewers (NB, MP, ZH or KH) extracted data from the full text papers on all 96 
studies included. The reviewers used a standard data extraction sheet, entered in duplicate into an 97 
electronic database (EpiData, version 3.1, Copenhagen, Denmark). Discrepancies were resolved by 98 
discussion. Bibliographic details (author, publication year), details of the population (e.g., sex, age, 99 
setting), sample size per comparison group and number of people lost to follow up, exposure (fish or 100 
n-3 capsules) and daily dosage, obesity-related phenotypes (e.g. BMI, waist circumference) before and 101 
after the intervention were all extracted. Furthermore, potential confounders accounted for and quality 102 
criteria like type of randomization or blinding of participants and outcome assessors were extracted. 103 
Study quality 104 
 105 
To assess the internal validity of the studies and the accuracy of reporting we followed published 106 
guidelines to a priori identify criteria that may be related to the risk of bias (26, 27): sequence 107 
generation, concealment of allocation, blinding of participants, blinding of clinicians, blinding of 108 
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outcome assessor, and intention-to-treat analyses. For each included study we noted whether the 109 
quality criteria were met or not, or if they were not described.  110 
Data analysis 111 
 112 
We combined data using fixed effects meta-analyses. We calculated mean differences in changes from 113 
baseline between the two comparison groups, with 95% confidence intervals. Standard deviations of 114 
changes from baseline were consistently reported only in three studies (18, 28, 29). Where standard 115 
deviations of changes from baseline were missing, we used the formula provided in the Cochrane 116 
Handbook of Systematic Reviews (20) to calculate standard errors and then converted them into 117 
standard deviations. In this formula we used a correlation coefficient of 0.8 for the outcome lean body 118 
mass, and 0.9 for the other outcomes, as reported in the studies.  119 
 Statistical evidence for heterogeneity between studies was assessed by the I2 statistic (30). Funnel 120 
plots were used to examine possible small study bias; we used a regression test to test for funnel plot 121 
asymmetry (31). We also performed stratified analyses and random-effects meta-regressions to assess 122 
the effect of study quality criteria, patient characteristics and intervention characteristics on the results. 123 
The statistical package Stata (version 11.2, Stata Corp. College Station, TX) was used for all analyses.  124 
Results 125 
Study selection 126 
 127 
We found 988 unique studies. After exclusions according to our criteria, we retrieved 38 studies as full 128 
text. Of these, 17 studies met the inclusion criteria, and we used 15 in the meta-analyses. We excluded 129 
two studies that reported results not in a format suited for meta-analysis. One (17) reported the 130 
outcomes as percentage of changes from baseline. This study showed no difference in body weight, 131 
waist circumference, fat mass and lean body mass between the fish-group and the control-group after a 132 
8-week diet. The other study (32) reported outcome data (BMI and waist circumference) as median 133 
and interquartile ranges. It showed no difference between intervention and control group after three 134 
years of follow-up. 135 
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Study characteristics of included studies 136 
 137 
Most studies were conducted in European countries (8 studies). Three were carried out in Australia, 138 
two in North America, two in Asia and one each in South America and in Africa (see Table 1 for a 139 
description of included studies). The populations studied were mainly Caucasian. Most participants 140 
were recruited from general populations; four were from hospital or outpatient populations. Sample 141 
sizes varied between 18 and 563, but were mostly smaller than 100. A total of 934 participants were 142 
included. Study duration varied between three weeks and three years; most studies lasted two to three 143 
months. Exposure was mostly through n3-PUFA capsules, which contained both EPA and DHA in 144 
different ratios. The daily dosage of total n3-PUFA varied between 157 mg and 3360 mg.  145 
Quality criteria (sequence generation, concealment of allocation, blinding of participants, clinician or 146 
outcome assessor, intention-to-treat analysis) appeared to have no effect on results. But the reporting 147 
quality of most studies was low (see Table 2), which made it difficult to determine the impact of study 148 
quality on our results. Only six studies reported on sequence generation, five on concealment of 149 
allocation, no study reported whether or not outcome assessors were blinded, and only three studies 150 
reported that they performed an intention-to-treat analysis.  151 
We did not find evidence for publication bias (see supporting information document S2). The 152 
regression test (body weight: p=0.31; BMI: p=0.63) did not indicate publication bias. 153 
Results of meta-analyses  154 
 155 
We gathered data suitable for meta-analyses for six different outcomes (body weight, BMI, body fat 156 
percentage, fat mass, waist circumference, and lean body mass). In general, meta-analyses showed a 157 
more pronounced change in body composition in intervention groups than in control groups (Figure 2 158 
and supporting information document S3). The heterogeneity between studies assessed by I2 statistics 159 
was 0% for all meta-analyses performed. 160 
The meta-analysis of outcome body weight (12 studies) showed more weight loss in the intervention 161 
groups than in the control groups (-0.59 kg, 95% CI: -0.96 to -0.21, p=0.002). For the outcome BMI 162 
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(13 studies), the meta-analysis showed a greater decrease in BMI in the intervention groups than in the 163 
control groups (-0.24 kg/m2, 95% CI: -0.40 to -0.08, p=0.003). Similarly, for the outcome body fat 164 
percentage (7 studies), the meta-analysis showed a greater decrease in the intervention groups than in 165 
the control groups (-0.49%, 95% CI: -0.97 to -0.01, P=0.047). Outcome waist circumference (7 166 
studies) was also reduced more in the intervention groups than in the control groups (-0.81 cm, 95% 167 
CI: -1.34 to -0.28, p=0.003).  168 
For the outcome fat mass (3 studies), the meta-analysis showed no statistically significant difference 169 
between intervention and control groups (-0.36 kg, 95% CI: -0.96 to 0.24, p=0.24). Similarly, for the 170 
outcome lean body mass (3 studies), the meta-analysis showed no statistically significant difference 171 
between intervention and control groups (-0.19 kg, 95% CI: -0.72 to 0.33, p=0.47).  172 
Sensitivity analyses and meta-regressions 173 
 174 
Results were not modified by exposure characteristics (type of exposure (fish or fish oil), EPA/DHA 175 
ratio, dose per day, study time or additional interventions like calorie restricted diet or exercise), or 176 
participant characteristics (ethnicity, setting, age, nutritional stage, health condition, sex). We found 177 
that length of study (less than 60 days versus more than 60 days) had a significant effect in the meta-178 
regression for the outcome BMI (p=0.028): the effect was stronger in shorter studies (see also Figure 179 
3). Stratified analyses by sex showed stronger effects of n3-PUFA on reduction of obesity related 180 
measures in males than in females, but this difference generally did not reach statistical significance  181 
(p>0.17). An exception was waist circumference (p=0.050): the meta-regression showed a stronger 182 
effect in men than in women (based on 3 studies).  183 
Discussion 184 
 185 
We found evidence that intake of fish or fish oil capsules can decrease weight in adults. When 186 
considered on their own, most studies did not show a statistically significant difference: our meta-187 
analyses documented effects that previous reviews had not detected (15, 16). We included only RCTs 188 
that explicitly examined body composition related measures as primary or secondary outcomes and 189 
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used n3-PUFA of fish provenience. Our analysis was therefore not compromised by the possibility 190 
that n3-PUFA derived from vegetal sources had different effects than n3-PUFA derived from fish 191 
(33).  Our study was, however, limited by poor reporting in the studies we examined. This made it 192 
difficult to assess the impact of study quality on results. 193 
The effect found in our meta-analyses was modest: 590 grams mean difference in body weight 194 
between intervention and control groups. This finding was consistent for other body composition 195 
related outcomes like BMI, body fat percentage and waist circumference. For outcomes body fat mass 196 
and lean body mass, the direction of results was the same. However, results were not statistically 197 
significant, probably because of a lack of statistical power, as only few studies reported on these 198 
outcomes. 199 
A modest weight loss of 5-10% body weight has been shown to be effective in improving risk factors 200 
like hyperinsulinemia, hypertension and dyslipidemia (34-36). Indeed, Klein concluded that modest 201 
weight loss can affect the whole cluster of cardiovascular risk factors simultaneously (37). Troseid and 202 
colleagues (32) found that despite small to moderate decreases in BMI, triglycerides and inflammatory 203 
markers such as IL-18 decreased after an n3-PUFA intervention, and an overall positive effect was 204 
obtained, probably by a combination of mechanisms. As obesity is associated with a low-grade 205 
inflammation state with mild elevation of several inflammatory markers expressed in adipose tissue, 206 
like TNF-α or IL-6 (38-40), the anti-inflammatory effect of n3-PUFA might have a beneficial effect. 207 
In fact, n3-PUFA was shown to reduce insulin resistance in rats and humans (41, 42) and proposed as 208 
a potential anti-inflammatory strategy to decrease obesity-related disease (43).  209 
At a population level the effect of a small change in a risk factor on an outcome can be substantial. 210 
This phenomenon is known as the “prevention paradox” (44) and relates to the fact that a large number 211 
of people exposed to a low risk produce more cases of disease than a small number of people exposed 212 
to a high risk. In fact, the population attributable risk depends on the individual attributable risk and 213 
the prevalence of the risk factor in the population. It is therefore more effective to shift the distribution 214 
of the risk factor (in this case overweight) in the whole population, than to treat only those at high risk 215 
(obese people), even if the shift in the population is modest. We found that taking n3-PUFA for less 216 
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than two months may be more effective than longer interventions. This finding questions the long term 217 
effect of n3-PUFA on body composition, but as only few studies lasted longer than two months and 218 
only one study lasted more than a year (32), more long-term studies are needed to clarify this point. 219 
In the present study, we found some indications that the effect might be greater in males than in 220 
females for the outcome waist circumference, which is a measure for visceral adiposity. This is 221 
relevant, as visceral fat is strongly associated with metabolic disease risks (45-47). Several studies 222 
reported that n3-PUFA had a stronger effect on weight loss in males than in females (e.g. (18)), while 223 
other studies found stronger effects in women (12). Difference between the sexes in the physiological 224 
response to n3-PUFA is plausible because men and women have a different fat tissue anatomy and 225 
physiology. For example, women may convert more alpha-linoleic acid into DHA than men do (48, 226 
49). A population based study in New Zealand showed higher DHA levels and lower EPA levels in 227 
serum lipids in females compared to males (50). Future studies on the effect of n3-PUFA on body 228 
composition should examine gender differences in order to clarify possible differences in health 229 
benefits.  230 
A further question is the relative importance of EPA and DHA. We did not find a dose-response 231 
relationship or an effect modification depending on the EPA / DHA ratio, despite both animal studies 232 
(51, 52) and human studies (28) suggesting this possibility. Several mechanisms have been proposed 233 
to explain the weight loss effect of n3-PUFA, for example increased lipolysis and reduced lipogenesis. 234 
In rodents (53) and in humans (54) n3-PUFA stimulate beta-oxidation, and inhibit fatty acid synthesis 235 
and VLDL secretion, partially by regulating gene expression. In rats, there is indication that n3-PUFA 236 
might reduce lipogenesis in adipose cells by reducing lipoprotein lipase (LPL) activity (55). In 237 
addition to n3-PUFA, fish protein might have an effect on body weight. For example, the amino acid 238 
taurine, which is abundant in fish protein, showed a weight lowering effect in mice (56, 57) and 239 
humans (58). In our meta-regressions, we did not find a difference between the effects of whole fish or 240 
of fish oil on body composition. However, only three studies included in our analysis used whole fish 241 
as exposure (17, 18, 59), so that more studies are needed using whole fish or fish protein to clarify the 242 
possible specific roles of fish oil and fish protein, and the different components of fish protein.  243 
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Our meta-analysis and other studies showed that n3-PUFA might influence body composition and 244 
health in a favorable way. Evolutionary considerations are also relevant in this context. Based on 245 
estimates from studies on Paleolithic nutrition and modern-day hunter-gatherer populations it seems 246 
likely that humans have evolved with a diet that contained small and approximately equal amounts of 247 
n6 and n3-PUFA and lower amounts of trans-fatty acids and linoleic acid (60). A nutrition rich in n3-248 
PUFA and other nutrients typical for the Paleolithic diet, such as polyphenols, fiber, and plant sterols, 249 
was therefore proposed to improve health outcomes (61). Of several early Homo species (such as 250 
Homo habilis, Homo erectus and early Homo sapiens) it is assumed that they consumed fish and 251 
seafood (62-64). However, the exploitation of aquatic food resources is still a neglected field in 252 
paleoanthropology (65, 66) and more research on the reconstruction of our ancient natural nutrition, 253 
including aquatic food, is needed (67). This knowledge should contribute to a better understanding of 254 
modern human nutrition and health. 255 
Conclusions 256 
 257 
Our meta-analysis showed that consumption of n3-PUFA can decrease weight in adults. Further 258 
research is needed to reveal which components of fish and fish oil are most beneficial. In particular, 259 
the documented positive effects of n3-PUFA on cardiovascular diseases, dyslipidemia and obesity 260 
suggest that we should continue to explore the effects of fish-derived n3-PUFA on human health.261 
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Table legends 262 
Table 1: Characteristics of studies included in the systematic review. Country and setting of the 263 
studies are given, as well as sample size per group, exposure used, and duration of studies. All except 264 
Abete 2009 and Troseid 2009 were included in the meta-analyses. 265 
Table 2: Quality criteria of studies included in the systematic review. The criteria chosen were: 266 
correct method of randomization, correct concealment of allocation, blinding of participants, clinicians 267 
and outcome assessors, and the application of an intention-to-treat data analysis. For each study it was 268 
stated if the criterion was met or not, or if it was not described (classified as unclear). Criteria that 269 
were not possible to meet (e.g., blinding for fish meals) were classified as non applicable.  270 
  271 
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Figure legends 272 
 273 
Figure 1: Flow chart of studies throughout the systematic review process. Numbers of studies found, 274 
selected and included or excluded were given for each review step, with reasons for exclusion in full 275 
text studies.  276 
Figure 2: Results of meta-analyses performed for different outcomes on the association between fish 277 
or fish oil intake and body composition. The number of datasets can be higher than the number of 278 
studies included, if some studies reported their results divided into subgroups (as for instance by 279 
intervention type or by sex). The mean differences between intervention and control groups and their 280 
95% confidence intervals are given for each outcome. Note that the unit of measure for each outcome 281 
is different. 282 
Figure 3: Forest-plot of meta-analysis on the association between fish or fish oil and BMI, by time of 283 
study duration. Studies are divided into two groups: less than two months of study duration vs. more 284 
than two months of study duration. Only studies of less than two months of study duration show a 285 
BMI-lowering effect of fish or fish oil. 286 
  287 
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Supporting information 288 
 289 
Supporting information document S1: Search strategy for the database Medline. The search 290 
strategies for the databases Embase and CENTRAL were similar. 291 
Supporting information document S2: Figure showing funnel plots of studies for the outcomes body 292 
weight (12 studies) and BMI (13 studies).  There was no indication for publication bias. 293 
Supporting information document S3: Forest plots of meta-analyses on the association between fish 294 
oil intake and body composition measures. Figure 1 shows the results for the outcome body weight, 295 
Figure 2 for the outcome BMI. Figure 3 shows the results for the outcome body fat percentage, Figure 296 
4 for the outcome waist circumference. Figure 5 shows the results for the outcome fat mass, Figure 6 297 
for the outcome lean body mass. For all outcomes the weighted mean difference between changes 298 
from baseline comparing intervention group and control group and 95% confidence intervals are 299 
given, as well as overall estimates. All meta-analyses were performed as fixed effects models, as no 300 
one showed evidence for heterogeneity. 301 
 302 
 303 
  304 
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Table 1: Characteristics of studies  306 
Reference Country Setting or population Intervention 
group (N, % 
males) 
Control 
group (N, 
% males) 
Exposure, per 
day (mg): EPA / 
DHA 
Duration of 
study 
(days) 
Abete 2009 
(17)† 
Spain General population  8 (100%) 10 (100%) 3 meals with fatty 
fish weekly 
56 
Bays 2009 
(29) 
USA Unclear 84 (71%) 83 (76%) 1860 / 1500 56 
Crochemore 
2012 (14) 
Brazil Hospital, high blood 
pressure and diabetes 
program 
28 (0%) 13 (0%) A: 547.5 / 352.5 
B: 328.5 /  211.5 
30 
DeFina 2011 
(68) 
USA General population 64 (31%) 64 (31%) 2500 / 500 168 
Ebrahimi 2009 
(6) 
Iran General population 47 (15%) 43 (9%) 180 / 120 180 
Emsley 2008 
(69) 
South Africa Community psychiatric 
services and university 
hospital 
39 (69%) 33 (70%) 2000 / 0 84 
Hill 2007 (70) Australia Unclear 33 (33%) 32 (41%) Total 6000 84 
Itariu 2012 
(71) 
Austria Bariatric surgery clinic 27 (15%) 28 (18%) 1840 / 1520 56 
Kabir 2007 
(11) 
France Diabetes department 
outpatient clinic 
12 (0%) 14 (0%) 1080 / 720 60 
Kunesova 
2006 (28) 
Czech 
Republic 
Unclear 11 (0%) 9 (0%) Total 2800 21 
Marqués 2008 
(59) 
Spain Follow up from 
SEAFOODPlus 
YOUNG Study 
14 (100%) 7 (100%) Total 1070 56 
Munro 2012 
(13) 
Australia General population 18 (17%) 14 (21%) 420 / 1620 98 
Munro 2013 
(12) 
Australia General population 20 (25%) 19 (21%) 420 / 1620 56 
Paniagua 
2011 (8) 
8 European 
countries 
LIPGENE study 83 (48%) 77 (44%) Total 1240 84 
Thorsdottir 
2007 (18) 
Iceland, 
Spain, 
Ireland 
SEAFOODPlus 
YOUNG Study  
244 (43%) 80 (40%) Total: cod: 300, 
salmon: 3000, 
capsules: 1500 
56 
Troseid 2009 
(32)† 
Norway Follow up from Oslo 
Diet and Antismoking 
Study | 
282 (100%) 281 (100%) 840 / 480   1095 
Yamaoka 
2007 (19) 
Japan Female college 
students 
57 (0%) 46 (0%) 0 / 700 35 
† = not included in meta-analyses. 307 
  308 
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Fig. 1: Flow chart of study selection. 492 
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Fig 2: Results of meta-analyses performed for different outcomes on the association between fish or 495 
fish oil intake and body composition. 496 
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Fig. 3: Forest-plot on the association between fish or fish oil and BMI, by time of study duration.  500 
 501 
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Table 1: Characteristics of studies  503 
Reference Country Setting or population Intervention 
group (N, % 
males) 
Control 
group (N, 
% males) 
Exposure, per 
day (mg): EPA / 
DHA 
Duration of 
study 
(days) 
Abete 2009 
(17)† 
Spain General population  8 (100%) 10 (100%) 3 meals with fatty 
fish weekly 
56 
Bays 2009(29) USA Unclear 84 (71%) 83 (76%) 1860 / 1500 56 
Crochemore 
2012 (15) 
Brazil Hospital, high blood 
pressure and diabetes 
program 
28 (0%) 13 (0%) A: 547.5 / 352.5 
B: 328.5 /  211.5 
30 
DeFina 2011 
(85) 
USA General population 64 (31%) 64 (31%) 2500 / 500 168 
Ebrahimi 2009 
(6) 
Iran General population 47 (15%) 43 (9%) 180 / 120 180 
Emsley 2008 
(86) 
South Africa Community psychiatric 
services and university 
hospital 
39 (69%) 33 (70%) 2000 / 0 84 
Hill 2007 (87) Australia Unclear 33 (33%) 32 (41%) Total 6000 84 
Itariu 2012 
(88) 
Austria Bariatric surgery clinic 27 (15%) 28 (18%) 1840 / 1520 56 
Kabir 2007 
(11) 
France Diabetes department 
outpatient clinic 
12 (0%) 14 (0%) 1080 / 720 60 
Kunesova 
2006 (28) 
Czech 
Republic 
Unclear 11 (0%) 9 (0%) Total 2800 21 
Marqués 2008 
(89) 
Spain Follow up from 
SEAFOODPlus 
YOUNG Study 
14 (100%) 7 (100%) Total 1070 56 
Munro 2012 
(14) 
Australia General population 18 (17%) 14 (21%) 420 / 1620 98 
Munro 2013 
(12) 
Australia General population 20 (25%) 19 (21%) 420 / 1620 56 
Paniagua 
2011 (8) 
8 European 
countries 
LIPGENE study 83 (48%) 77 (44%) Total 1240 84 
Thorsdottir 
2007 (18) 
Iceland, 
Spain, 
Ireland 
SEAFOODPlus 
YOUNG Study  
244 (43%) 80 (40%) Total: cod: 300, 
salmon: 3000, 
capsules: 1500 
56 
Troseid 2009 
(32)† 
Norway Follow up from Oslo 
Diet and Antismoking 
Study | 
282 (100%) 281 (100%) 840 / 480   1095 
Yamaoka 
2007 (19) 
Japan Female college 
students 
57 (0%) 46 (0%) 0 / 700 35 
† = not included in meta-analyses.504 
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Table 2: Methodological quality of studies  505 
Reference Sequence 
generation 
Concealment of 
allocation 
Blinding participants  Blinding 
investigator 
Blinding 
outcome 
assessor 
ITT 
Abete 2009 unclear unclear n. a. n. a.  unclear unclear 
Bays 2009 unclear unclear yes yes unclear unclear 
Crochemore 2012 uclear unclear yes no no unclear 
DeFina 2011 unclear unclear yes unclear unclear yes 
Ebrahimi 2009 unclear unclear no no unclear no 
Emsley 2008 unclear unclear yes yes unclear yes 
Hill 2007 unclear unclear yes unclear unclear no 
Itariu 2012 yes yes n. a. n. a. unclear yes 
Kabir 2007 unclear unclear yes yes unclear unclear 
Kunesova 2006 unclear unclear yes unclear unclear unclear 
Marqués 2008 yes unclear n. a. n. a. unclear unclear 
Munro 2012 yes yes yes yes unclear unclear 
Munro 2013 yes yes yes yes unclear unclear 
Paniagu 2011 yes yes unclear unclear unclear unclear 
Thorsdottir 2007 unclear unclear n. a. n. a. unclear unclear 
Troseid 2009 yes yes yes yes unclear unclear 
Yamaoka 2007 unclear unclear n. a. n. a. unclear unclear 
ITT = intention-to-treat analysis performed; n. a. = non applicable. 506 
 507 
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 509 
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